Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tibet Duo Rui Pharmaceutical Co (301075) Fair Value & Analysis

Healthcare · CN · Market cap 5.5B CNY

Price¥65.34
Fair Value¥32.32
Upside-50.5%
Quality89/100
Evidence: Low Range ¥24.24 – ¥40.40

Analysis

Tibet Duo Rui Pharmaceutical Co (301075) currently trades at ¥65.34, while our model-based Fair Value estimate is ¥32.32 — implying the stock looks roughly 50.5% overvalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, intermediates, and raw materials in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as sodium acetate ringer's injection; and agent products, such as amoxicillin sodium and clavulanate potassium for injection, etc. The company was founded in 2005 and is headquartered in Tibet, China.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1827% Jiangsu Hengrui Pharmaceuticals Co (600276) -43% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -24% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -81%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.